













- pH in situ by plastic pH electrode in patients with coeliac disease. *Scand J Gastroenterol* 22: 377-384.
58. Leserman L, Machy P, Leonetti JP, Milhaud PG, Degols G, et al. (1990) Targeted liposomes and intracellular delivery of macromolecules. *Prog Clin Biol Res* 343: 95-102.
59. Aramaki Y, Tomizawa H, Hara T, Yachi K, Kikuchi H, et al. (1993) Stability of liposomes in vitro and their uptake by rat Peyer's patches following oral administration. *Pharm Res* 10: 1228-1231.
60. Tsubery H, Mironchik M, Fridkin M, Shechter Y (2004) Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. *J Biol Chem* 279: 38118-38124.
61. Nguyen S, Alund SJ, Hiorth M, Kjoniksen AL, Smistad G (2011) Studies on pectin coating of liposomes for drug delivery. *Colloids Surf B Biointerfaces* 88: 664-673.
62. Iwanaga K, Ono S, Narioka K, Morimoto K, Kakemi M, et al. (1997) Oral delivery of insulin by using surface coating liposomes - improvement of stability of insulin in gi tract. *Int J Pharm* 157: 73-80.
63. Bickerdike MJ, Thomas GB, Batchelor DC, Sirimanne ES, Leong W, et al. (2009) NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke. *J Neurol Sci* 278: 85-90.
64. Langer R (2000) Biomaterials in drug delivery and tissue engineering: one laboratory's experience. *Acc Chem Res* 33: 94-101.
65. De Jong WH, Borm PJ (2008) Drug delivery and nanoparticles: applications and hazards. *Int J Nanomedicine* 3: 133-149.
66. Jain A, Jain A, Gulbake A, Shilpi S, Hurkat P, et al. (2013) Peptide and protein delivery using new drug delivery systems. *Crit Rev Ther Drug Carrier Syst* 30: 293-329.
67. Mu L, Feng SS (2003) A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. *J Control Release* 86: 33-48.
68. Sakuma S, Suzukia N, Kikuchia H, Hiwatarib K, Arikawab K, et al. (1997) Oral peptide delivery using nanoparticles composed of novel graft copolymers having hydrophobic backbone and hydrophilic branches. *Int J Pharm* 149: 93-106.
69. El-Shabouri MH (2002) Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. *Int J Pharm* 249: 101-108.
70. Pan Y, Li YJ, Zhao HY, Zheng JM, Xu H, et al. (2002) Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. *Int J Pharm* 249: 139-147.
71. Cui F, Zhang L, Zheng J, Kawashima Y (2004) A study of insulin-chitosan complex nanoparticles used for oral administration. *J Drug Deliv Sci Technol* 14: 435-439.
72. Prego C, Torres D, Fernandez-Megia E, Novoa-Carballal R, Quinoa E, et al. (2006) Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. *J Control Release* 111: 299-308.
73. Vyas SP, Venugopalan P, Sood A, Mysore N (1997) Some approaches to improve bioavailability of peptides and proteins through oral and other mucosal routes. *Pharmazie* 52: 339-345.
74. Saffran M, Kumar GS, Savariar C, Burnham JC, Williams F, et al. (1986) A new approach to the oral administration of insulin and other peptide drugs. *Science* 233: 1081-1084.
75. Yamamoto A, Taniguchi T, Rikyu K, Tsuji T, Fujita T, et al. (1994) Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. *Pharm Res* 11: 1496-1500.
76. Davis SS (1992) Developing delivery systems for peptides and proteins. in *Scrip Magazine* 34-38.
77. Bai JP, Chang LL, Guo JH (1995) Targeting of peptide and protein drugs to specific sites in the oral route. *Crit Rev Ther Drug Carrier Syst* 12: 339-371.
78. Hita V, Singh R, Jain SK (1997) Colonic targeting of metronidazole using azo aromatic polymers: Development and characterization. *Drug Delivery* 4: 19-22.
79. Ashford M, Fell J, Attwood D, Sharma H, Woodhead P (1993) An evaluation of pectin as a carrier for drug targeting to the colon. *J Control Release* 26: 213-220.
80. von der Ohe MR, Camilleri M, Kvols LK, Thomforde GM (1993) Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. *N Engl J Med* 329: 1073-1078.